Kornimate/medical-research-clean huggingface dataset:
role and molecular mechanism of farnesoid x receptor(fxr) and ripk3 in the formation of acute respiratory distress syndrome in neonates

Conditions: Acute Respiratory Distress Syndrome; Acute Lung Injury; FXR; RIPK3

Summary: in the clinical data, the changes of ripk3 and fxr were monitored in the lung lavage fluid and blood from the patients. in vivo experiments to find high risk factors to induce aec necrosis and further lead to ards evidence, can provide a more direct theoretical research foundation for the pathogenesis of ards.

divided into 3 arms ali :diagnostic criteria: 1.acute onset；2.fio2/ pao2\ 35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (mas) understanding of history, and with the exception of the primary pulmonary surfactant (ps) lack of. ards :pediatric acute respiratory distress syndrome (ards) is a severe lung injury caused by pneumonia, sepsis, and trauma.diagnostic criteria: 1.acute onset；2.fio2/ pao2\ 35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (mas) understanding of history, and with the exception of the primary pulmonary surfactant (ps) lack of；6.need to use a ventilator. control group: patients with mechanical ventilation due to external causes of the lung, no ali-ards performance,fio2/ pao2\< 40.0 kpa (300 mmhg), such as premature apnea or hie.

Eligibility criteria:
inclusion criteria:according to the diagnostic criteria, the diagnosis was ali or ards； exclusion criteria:severe congenital or hereditary disease of the newborn, is clearly diagnosed as nrds, which is caused by the lack of the primary ps。

Keywords: fxr ripk3 neonates acute respiratory distress syndrome acute lung injury
v-boost immunotherapy in glioblastoma multiforme brain cancer

Conditions: Glioblastoma Multiforme; Glioma of Brain

Summary: the phase ii study to determine the safety and efficacy of v-boost in treating a type of brain cancer called glioblastoma multiforme (gbm). v-boost is an immunotherapy in which the patient's immune system will be modulated to eliminate tumor cells. v-boost is made as an oral tablet which contains specially formulated hydrolyzed gbm antigens along with alloantigens. patients are either newly diagnosed or with recurrent form of gbm who may have been subjected to surgery and/or chemo- or radiation therapy that ended up unsuccessful. the goal is to eradicate gbm tumor cells through daily oral administration of one pill of v-boost immunotherapeutic vaccine, which so far has not shown any adverse reaction.

the proposed phase ii trial is an-open label study of the safety and efficacy of v-boost in newly diagnosed or treatment-refractory patients with glioblastoma multiforme (gbm) following unsuccesfull resection and/or chemoradiation. the phase i clinical tria,l carried out in a small, open-label study, demonstrated safety and promising efficacy. the purpose of this study is to gain additional information from a larger clinical trial aimed to recruit at least 20 patients with gbm. patients may be newly diagnosed with gbm or are those who have been subjected to resection and/or chemotherapy or radiation, but without success. patients need to have imaging records and health assessment prior to study enrollment. those on chemotherapy or radiation can be in washout period or may receive immunotherapy concurrently. patients will be administered daily dose of v-boost oral tablet for at least one month and additional dosing can be envisaged depending on outcome of first month. the primary objective is to evaluate the effect on tumor size and progression free survival (pfs) in comparison to patients on standard of care.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of gbm * ≥ 5 years of age * consent from parents or legal guardian if under-aged exclusion criteria: * severe pulmonary, cardiac or other systemic disease * presence of an acute infection requiring active treatment with antibiotics/antivirals * receiving corticosteroids (e.g., dexamethasone) during study duration

Keywords: brain cancer
efficacy and security of an endovascular treatment as first choice procedure compared with a standard intravenous thrombolytic therapy treatment for patients with acute ischemic stroke within 4.5 hours after onset

Conditions: Acute Ischaemic Stroke

Summary: this study will compare two ways of treatment for acute ischemic stroke: an endovascular treatment (evt), defined as intraarterial thrombolysis and/or mechanical thrombectomy as a first choice treatment versus intravenous thrombolytic therapy (ivt) only or followed by evt in patients with acute ischemic stroke due to a main brain artery occlusion within 4.5 hours after onset. patients treated with ivt only or with ivt followed by evt will be analyzed separately.


Eligibility criteria:
inclusion criteria: * 80 or less years old patients with acute stroke produced by a main artery occlusion * nihss national institutes of health stroke scale score greater than 6 (severe neurological impairment) * patients receiving evt or ivt within 4.5 hours after onset exclusion criteria: * evt or ivt contraindication * previous neurological impairment, severe concomitant disease or poor prognosis. * pregnancy or breastfeeding * known hypersensitivity to any study drugs * severe organic disease for which there is not risk compensation.

Keywords: ischaemic stroke main artery occlusion endovascular treatment intravenous thrombolytic therapy
measurements of corneal biomechanical properties using a dynamic scheimpflug analyzer for young healthy adults in south korea

Conditions: Myopia

Summary: the human cornea is affected by the magnitude and velocity of both internal and external forces because the cornea has both static and dynamic resistance components. considering these natures of the human cornea, many investigators have tried to demonstrate corneal biomechanical properties to understand these characteristics of the cornea. corneal biomechanical properties are known to influence the accuracy of measurements in intraocular pressure (iop) and are recognized as important factor to explain the susceptibility of development of glaucomatous damage. until recently, the only instrument which enabled the in vivo measurements of the ocular biomechanical properties was ocular response analyzer (ora, reichert ophthalmic instruments, depew, ny, usa).8 the ora has been used to assess the biomechanical properties of the cornea according to the dynamic bidirectional applanation process. a dynamic scheimpflug analyzer (corneal visualization scheimpflug technology \[corvis st\], oculus, wetzlar, germany) has been introduced recently and has become a useful instrument for evaluating corneal biomechanical properties. the dynamic scheimpflug analyzer captures the dynamic process of corneal deformation caused by an air puff using an ultra-high-speed scheimpflug camera at a rate of up to 4,330 images per second. until now, well-organized analysis on the normative data of the corneal biomechanical profiles measured with the dynamic scheimpflug analyzer for young healthy adults has not been reported yet. hence, in the present study, we aim to conduct normative data analysis for the corneal biomechanical properties with the dynamic scheimpflug analyzer in a cohort of young healthy adults in south korea.


Eligibility criteria:
inclusion criteria: * participants will be included in analyses if they are 20 to 40 years of age * participants who have myopia with a spherical equivalent (se) between 0.00 and -11.00 diopters (d) exclusion criteria: * participants will be excluded from analyses if they had previous ocular or intraocular surgery, a visual field defect, suspicious optic disc appearance, iop ≥ 30 mmhg, or presence of corneal abnormalities such as keratoconus and forme fruste keratoconus, corneal scarring that would preclude accurate measurements.
a study on telemedicine applied to actual outpatient clinic for epilepsy

Conditions: Epilepsy

Summary: this is an observational study to confirm the non-inferior effectiveness on health outcomes of tele-counseling or tele-prescription, which was the first outpatient system applied to the actual medical sites in korea during the coronavirus disease 2019 (covid-19) pandemic. researchers collect data using electronic medical records and questionnaires to patients and their caregivers who are continuously receiving outpatient treatment for epilepsy at a single center. the results of the study will be presented by comparing the health outcomes between the non-face-to-face care group and the usual care group.

during the covid-19 pandemic, temporary phone consultations or prescriptions are being conducted at actual medical sites in korea. now, interest about non-face-to-face medical care and expectation that this medical service will be available in the post covid-19 era are increasing. the aim to study non-inferior effectiveness of health outcomes for epilepsy by comparing non-face-to-face care with usual care. in this observational study, two groups are recruited in a matched pair parallel in 1:2 allocation at single outpatient clinic. and then investigators collect data such as seizure control, adherence to treatment, adverse drugs reactions by using electronic medical records and questionnaires. because epilepsy, the target disease of the study, has chronic and recurrent symptoms, it is necessary for patients to visit the hospital regularly to check their condition. however, there are few neurologists in the province who can treat epilepsy. so that patients and their caregivers spend a lot of time and money traveling long distances to get treatment.

Eligibility criteria:
inclusion criteria: * those who have received outpatient treatment for epilepsy at least twice from the department of neurology, department of pediatrics, samsung medical center as of the date of participation in the study * those who have been taking one or more anticonvulsants for 3 months or more as of the date of participation in the study * those who have passed more than one month from the date of discharge from the hospital as of the date of participation in the study (however, hospitalization for examination only does not fall under this standard) exclusion criteria: * those who have an experience of inpatient treatment within 1 month as of the date of participation in the study (however, hospitalization for examination only is not classified as hospitalization under this standard) * those who have a record of visiting the emergency room within 1 month as of the date of participation in the study (however, visits that are not for epilepsy drug control are not classified as emergency room visits according to this standard) * those who have been diagnosed with psychogenic non-epileptic seizure (pnes) through electroencephalogram (eeg)

Keywords: telemedicine telehealth non-face-to-face
rejuvesol® washed rbc in sickle cell patients requiring frequent transfusions

Conditions: Sickle Cell Disease

Summary: the objective of this proposal is to test the feasibility of red blood cell (rbc) rejuvenation to chronic transfusion in sickle cell disease (scd) and the potential benefit of rbc rejuvenation in this population to determine if a larger clinical trial powered to definitively characterize the benefits of rejuvenation is warranted. this is a small pilot study is to see if restoring important energy molecules (atp and 2,3,dpg) in stored red blood cells before they are transfused, with a rejuvenating solution (rejuvesol), offers any advantages to individuals over standard blood transfusion. subjects will receive either rejuvenated (r) or standard (s) rbcs with each transfusion for 6 transfusions (over approximately a 6-month period) in a pre-defined order to maximize detection of any signal.

blood transfusion is part of the standard care for individuals that have sickle cell disease. often these transfusions become needed quite frequently. the purpose of the red blood cells in the blood is to deliver oxygen to the organs and tissues of the body. people with sickle cell disease have abnormal red blood cells. stored blood undergoes some changes that may make it less effective in achieving this goal. the purpose of this study is to see if restoring important energy molecules (atp and 2,3,dpg) in stored red blood cells before they are transfused, with a rejuvenating solution (rejuvesol), offers any advantages to individuals over standard blood transfusion. this is a food and drug administration (fda) approved process that is described by the american association of blood banks for prolonging blood storage but not used for everyday transfusions. the investigators want to use this process to improve blood transfused to individuals who need frequent transfusions. potential advantages include better delivery of oxygen by the transfused red blood cells and easier release of oxygen to the tissues. in addition the study will assess how using the rejuvenated blood affects the interval between transfusions. this means possibly that transfusions may not be needed as often. although rejuvesol has been previously approved by the fda, it is not routinely used to prepare standard blood transfusions to individuals who have sickle cell disease. use of rejuvesol in this study is considered investigational.

Eligibility criteria:
inclusion criteria: * stable, compliant, chronically transfused sickle cell disease (scd) patients * currently maintained crisis-free with repeated rbc therapy for at least 3 consecutive sessions * ≥18 years old * have hb ss disease * have the capacity to give informed consent exclusion criteria: * baseline need for washed rbcs * pre-treatment sao2 \< 92%.
fes to improve crouch gait in cp

Conditions: Cerebral Palsy; Gait

Summary: the overall goal of the proposed work is to develop and to assess the feasibility of using functional electrical stimulation (fes) system to improve crouch gait in individuals with cerebral palsy that may prevent the typical downward spiral of walking function decline in individuals with cp that occurs from adolescence into adulthood.

aim 1: to assess the feasibility of using a multiple channel fes system to produce an immediate neuroprosthetic effect to reduce crouch gait in children and adolescents with spastic diplegic cp. aim 2: to assess the feasibility of using a multiple channel fes system as a therapeutic training tool to produce lasting neurotherapeutic effects of diminished crouch gait in children and adolescents with cp.

Eligibility criteria:
inclusion criteria: * age 10-18 * spastic cp (di-, tetra-, or triplegia) * levels i-ii gmfcs classification * sufficient covering of the femoral head in the acetabulum (migration % \< 40) * mild crouch gait (minimum knee flexion 21-40o during stance) * potential to gain \> 20 degrees knee extension improvement in stance phase * minimum of 0o ankle dorsiflexion passive range of motion (prom) * visual, perceptual, cognitive, and communication skills to follow multiple step commands for attending to exercise and data collection * seizure-free or well controlled seizures exclusion criteria: * athetoid, ataxic, or hemiplegic cp * significant scoliosis (primary curve \> 40°) * spinal fusions extending into the pelvis * severe tactile hypersensitivity * joint instability or dislocation in lower extremity * lower extremity surgery or fractures in the past year * botox injections to lower extremity in the past 6 months * implanted medical device contraindicated with application of fes * severe spasticity in lower extremity (mod ashworth 4) * lower extremity joint pain during walking * hx of pulmonary disease limiting exercise tolerance or hx of cardiac disease * severely limited range of motion / contractures (\>15o knee flex or \>15o hip flex contractures) * pregnancy

Keywords: cerebral palsy functional electrical stimulation neurotherapeutic
effects of case management for patients with rheumatoid arthritis in taiwan

Conditions: Case Management; Rheumatoid Arthritis; Effectiveness

Summary: case management (cm) has been recommended as a way of inspiring measurable changes in individual behaviors and improving clinical outcomes for patients with chronic diseases. however, data on its effectiveness for taiwanese patients with rheumatoid arthritis (ra) are limited. this study aimed to determine the long-term effectiveness of cm that focused on nurses' role among taiwanese ra patients. a quasi-experimental pre-post test, control-group study with purposive sampling recruited ra patients from a hospital in taiwan during 2016-2017. cm program was composed of health education sessions and follow-up telephone consultations over a six-month period. a review of medical records and structured questionnaires yielded data about patient demographics and disease characteristics, and included chinese version of the arthritis self-efficacy scale and the taiwanese depression questionnaire. a comparison of the long-term effectiveness of the cm program was made using generalized estimating equation. this evidence-based study may be beneficial to characterize the long-term effectiveness of cm for taiwanese patients with ra, and may be a reference for healthcare providers in facilitating the provision of appropriate interventions to improve the adaptation processes and clinical outcomes for them.

nurse-led case management integrates a multi-component intervention comprised of health education and professional advice, as well as referral of clients to other health care team members, discussion of daily life plans, making an appointment for the next clinic, and conducting follow-up sessions by telephone.

Eligibility criteria:
inclusion criteria: * being at least 20 years old at the time of recruitment * being able to express opinions in either mandarin or taiwanese, and * having a diagnosis of rheumatoid arthritis (ra). exclusion criteria: * those having no cognitive impairment and severe complications will be excluded.
hearing implant performance in adults with low-frequency residual hearing

Conditions: Sensorineural Hearing Loss; Low-Frequency Residual Hearing

Summary: the purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the ci624 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.


Eligibility criteria:
inclusion criteria: 1. 18 years-of-age or older at the time of surgery. 2. low-frequency threshold at 500 hz ≤ 50 db hl and high-frequency pure-tone average (pta), 2000-8000 hz ≥ 65 db hl in the ear to be implanted. 3. pure-tone average (pta) (0.5k, 1k, 2k hz) \> 30 db hl in the contralateral ear. 4. cnc word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear. 5. english spoken as a primary language. 6. willing and able to provide written informed consent. exclusion criteria: 1. individuals older than 70 years at the time of surgery. 2. duration of severe to profound sensorineural hearing loss \> 20 years per self-report. 3. onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age. 4. ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. conductive overlay of 15 db or greater at two or more frequencies, in the range of 250 through 1000 hz in the ear to be implanted. 6. hearing loss of neural or central origin. 7. diagnosis of auditory neuropathy. 8. active middle-ear infection. 9. medical or psychological conditions that contraindicate undergoing surgery as determined by the investigator. 10. unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the investigator. 11. additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the investigator. 12. unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator. 13. investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling). 14. cochlear employees or employees of a contract research organization (cro) or contractors engaged by cochlear for the purposes of this investigation. 15. currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.
kinematic-based bont-a injections for bilateral et

Conditions: Essential Tremor

Summary: the primary objective is to study the efficacy of botulinum toxin type a (xeomin®) injected utilizing kinematically-based injection parameters for the treatment of upper extremity essential tremor (et). additional objectives are to study the benefit of kinematic assessment tools in determining injection parameters and to study the composition of tremor using kinematics.


Eligibility criteria:
inclusion criteria: * consenting male and female participants * diagnosis of 'definite essential tremor' in accordance with the trig criteria including: et individuals diagnosed with upper limb tremor in their motor dominant and non-dominant hands * stable et medication management for the 3 month duration prior to their enrollment in the study * participants who are botulinum toxin naïve for tremor management * patients will be screened for pregnancy by the physician exclusion criteria: * history of stroke * muscle weakness or any related compartmental muscle syndrome * smoking * history of als or myasthenia gravis * offending medications (lithium, valproate, steroids, amiodarone, beta-adrenergic agonists (e.g. salbutamol) * persons prescribed zonisamide * history of allergic or side effect reaction to botulinum toxin * contraindications per the xeomin® drug monograph * women reporting that they are pregnant

Keywords: movement disorders botulinum toxin type a kinematics
a study to determine the safety & efficacy of autologous human platelet lysate (hpl) in treatment of dark circles

Conditions: Periorbital Hyperpigmentation (Dark Circles)

Summary: this is a multicentre, open label, randomized, pilot study to evalute safety and efficacy of human platelet lysate (hpl) in subjects with periorbital hyperpigmentation. the study is being conducted at 2 centers in india.the primary endpoints are physicians and patient self assessment score. the secondary endpoints are improvement in photographic assessment form randomization to end of study.


Eligibility criteria:
inclusion criteria: * subjects (male and female), aged 18 to 55 years (both inclusive) with periorbital hyperpigmentation. * subject willing to refrain from any other treatment of periorbital hyperpigmentation during entire study duration. * subjects who are willing to give informed consent and adhere to the study protocol. exclusion criteria: * subjects aged less than 18 and more than 55 years * subjects with history of connective tissue disease. * subjects with metabolic or hematopoietic disorders * subjects unwilling to or unable to comply with the study protocol. * subjects taking concomitant therapy that might interfere with the study results in the investigator's opinion or participating in another trial in the past 30 days.